| |OCTOBER 20238CHIME, PANOLOS COLLABORATE TO IMPROVE MULTI-SPECIFIC THERAPEUTIC PROTEINSGLOBAL INSULIN SYRINGES MARKET IN A GROWTH TRAJECTORY TO REACH REVENUE OF USD 408.67 MILLIONPanolos Bioscience, a biopharmaceutical company focused on the development of multi-specific therapeutics to treat cancer, auto-immune diseases, and rare diseases, has formed a collaboration with Chime Biologics, a CDMO, for the development of PB203, a novel multi-specific protein drug for solid tumors (PDAC/ICC), which is currently in the preclinical stage with plans to conduct a Phase I trial in the United States.Chime Biologics will provide CMC services for the development and manufacture of PB203 from cell line development, process development, and GMP manufacturing. It will be based on Chime's CHOrus platform, which has a highly productive, rapid, and stable cell line development capability to select the optimal stable expression clones based on expression titer and quality, as per contractpharma.HyeSeong Lim, Founder and CEO of Panolos Bioscience, said, "We are pleased to be a global strategic partner with Chime Biologics, and the co-development of PB203 is an important start in establishing our long-term strategic cooperation in Wuhan, China, covering commercial manufacturing. This is the first step in our shared mission to the commercialization of innovative medicines, starting from China and spreading to the world. By partnering with global CDMO Chime Biologics, we will do our best to bring hope and a new life to our patients." POThe global Insulin Syringes Market is on the cusp of substantial growth, with projections indicating an impressive increase of $408.67 million during the period from 2022 to 2026. This growth trajectory is marked by a robust Compound Annual Growth Rate (CAGR) of 4.69% throughout the forecast period.The Insulin Syringes market growth is driven by several key factors, including the increasing global burden of diabetes, favorable government initiatives, and the availability of diabetes self-management education programs. As diabetes continues to be a global health concern, the demand for insulin syringes is expected to rise significantly.The increase in awareness programs for diabetes as one of the primary drivers fueling the growth of the Insulin Syringes Market in the coming years. Additionally, the market is expected to benefit from rising strategic partnerships aimed at boosting insulin syringe sales and an increasing focus on smart insulin syringes.The vendor analysis designed to help clients enhance their market positioning. It includes a detailed examination of several leading vendors in the Insulin Syringes Market, such as AdvaCare Pharma, ASP Healthcare Pty Ltd., Avantor Inc., B. Braun SE, Becton Dickinson and Co., Cardinal Health Inc, CODAN Medizinische Gerate GmbH and Co KG, Gerresheimer AG, Healthwarehouse.com Inc., Hi-Tech Medics Pvt Ltd., Hindustan Syringes and Medical Devices Ltd., LAC Healthcare Solutions, Nipro Corp., Novo Nordisk AS, Poly Medicure Ltd., SCHOTT AG, Smiths Group Plc, Terumo Corp., Thermo Fisher Scientific Inc., and UltiMed Inc. POTOP STORIES
< Page 7 | Page 9 >